The efficacy and role of Osimertinib/Tagrisso: How to help patients with non-small cell lung cancer prolong survival

Osimertinib/Tagrisso (Osimertinib) is a third-generation targeted therapy drug widely used to treat non-small cell lung cancer (NSCLC). Especially suitable for patients with positive EGFR (epidermal growth factor receptor) mutations, osimertinib has achieved remarkable results in the field of cancer treatment by precisely inhibiting the proliferation and spread of cancer cells. As an oral drug, the efficacy and role of osimertinib have been widely verified clinically, especially in prolonging patient survival and reducing side effects.

The main mechanism of action of osimertinib is through selective inhibition of mutated EGFR, especially the T790M mutation. EGFR is a receptor on the cell surface, and its activation promotes the proliferation and growth of tumor cells. In many patients with non-small cell lung cancer, mutations in the EGFR gene cause cells to grow out of control and form tumors. Osimertinib can specifically block the activity of these mutant EGFRs, thereby effectively inhibiting the growth and spread of tumors. It not only has a therapeutic effect on common EGFR mutations, but can also overcome the resistance of some first- and second-generation EGFR inhibitors. Especially in patients with T790M mutation-positive patients, osimertinib has shown excellent efficacy.

In addition, osimertinib has the ability to cross the blood-brain barrier, which means it is also effective in patients with non-small cell lung cancer who have brain metastases. Brain metastasis is a common complication in patients with advanced lung cancer, and traditional treatments are often difficult to effectively control brain lesions. The unique effect of osimertinib makes it an ideal choice for the treatment of patients with brain metastatic non-small cell lung cancer.

In terms of efficacy, osimertinib has been shown to significantly prolong patients' progression-free survival (PFS) and overall survival (OS). Multiple clinical studies have shown that compared with traditional chemotherapy or early EGFR inhibitors, osimertinib can provide more durable effects and have relatively mild side effects. Common side effects include rash, diarrhea, and mild respiratory discomfort, but these are usually mild and better tolerated than other medications.

Reference materials:https://go.drugbank.com/drugs/DB09330